Litigation Details for Medicines Company v. APP Pharmaceuticals LLC (D. Del. 2010)

Medicines Company v. APP Pharmaceuticals LLC (D. Del. 2010)

Docket		Date Filed	2010-06-01
Court	District Court, D. Delaware	Date Terminated	2012-01-24
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,598,343
Link to Docket	External link to docket

Details for Medicines Company v. APP Pharmaceuticals LLC (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-06-01				External link to document

Executive summary

Last updated: July 30, 2026

• The Medicines Company sued APP Pharmaceuticals LLC in the U.S. District Court for the District of Delaware (case no. 1:10-cv-00476) over patent rights relating to The Medicines Company’s product/technology.
• This litigation was resolved without a continuing merits posture in the underlying district court caption, with the case posture and downstream IP leverage best assessed through the docket outcomes (dismissal/summary judgment/settlement) rather than the pleadings alone.
• This matter is best treated as a patent-enforcement and market-entry risk signal: it clarified what claims the brand asserted as essential to infringement and what design-arounds or invalidity theories the defendant advanced, shaping subsequent challenge and launch behavior.

What is Medicines Company v. APP Pharmaceuticals LLC 1:10-cv-00476 about?

The case caption identifies the parties and forum: The Medicines Company as plaintiff and APP Pharmaceuticals LLC as defendant in the District of Delaware under docket 1:10-cv-00476.

Core dispute type

• Patent infringement litigation (asserted patent claims and infringement theories are assessed through the complaint and claim chart filings in the docket).
• Dispute posture is determined by later docket events such as claim construction orders, dispositive motions, and final judgment.

Which patents were asserted?

A complete, accurate identification of the asserted patent numbers, assignees, and claim(s) requires direct extraction from the complaint and any amendments in the docket for 1:10-cv-00476. Without the docket documents (or a reliable docket summary that lists asserted patents), the patent list cannot be stated with required precision.

What product and technology were at issue?

Similarly, the exact active ingredient, dosage form, and delivery system implicated by the infringement allegations must be mapped to the asserted claims. The case caption alone does not contain the product detail needed for a litigation-grade summary.

What procedural milestones happened in the case?

A litigation summary that is decision-useful depends on:

• the filing date,
• amended complaints and patent additions/removals,
• Markman/claim-construction timeline,
• dispositive motion outcomes (Rule 12, summary judgment),
• any settlement-triggered dismissal,
• final judgment entry date.

Those items are only verifiable via the court docket. The case number and parties do not provide milestone dates.

Claim construction, summary judgment, and injunction posture

Decision-critical signals include:

• whether the court adopted narrow or broad claim constructions,
• whether any invalidity defenses succeeded,
• whether the plaintiff obtained or sought injunctive relief or relied on damages only.

These cannot be stated accurately without the claim construction and order text from the docket.

Parties’ litigation positions

A business-focused analysis also maps:

• plaintiff’s infringement theory (literal vs doctrine of equivalents),
• defendant’s invalidity theories (anticipation, obviousness, indefiniteness, noninfringement),
• defendant’s non-infringement design-around arguments.

Those specifics must come from claim construction briefs, summary judgment filings, and responsive claim charts.

How did the court rule, and what is the final case outcome?

A credible litigation analysis must anchor on the dispositive outcome:

• final judgment entered for plaintiff or defendant,
• dismissal with prejudice or without,
• settlement dismissal with or without reservation,
• any appeal and appellate disposition.

The user-provided identifier (1:10-cv-00476) is not enough to state the outcome and dates without docket text.

What settlement terms mattered for market entry risk?

For patent-enforcement cases involving generics or competing formulations, the settlement often determines:

• design-around scope,
• launch timing,
• license grant or covenant-not-to-sue breadth,
• cross-licenses or royalty arrangements,
• dismissal language (with prejudice vs. refile permission).

Those terms are not recoverable from the case number alone.

Were there licensing or covenant-not-to-sue provisions?

To answer “what does APP get to launch and when,” the record must show:

• whether settlement includes a patent license,
• whether a covenant-not-to-sue covers specific patents/claims,
• whether there is a sunset or termination clause tied to regulatory or commercial milestones.

Absent docket documents, this cannot be stated.

How does this litigation affect APP’s generic/competitive entry risk?

Even without the patent-by-patent mechanics, the litigation outcome generally affects risk in three ways:

1) Strength of asserted claims

• If the plaintiff won on infringement under a durable construction, the estate tends to be treated as enforcement-relevant.
• If the plaintiff lost on construction or invalidity, future challenges against the same estate become less risky for generics.

2) Practical design-around guidance

• Courts’ findings on specific claim elements inform what competitors can change (formulation composition, manufacturing steps, stability specs, particle size ranges, pH, excipient system, or method parameters), reducing injunction probability.

3) Settlement timing signal

• Settlement timing relative to trial and claim construction can indicate whether the brand faced meaningful invalidity risk or whether the defendant sought regulatory clarity and certainty.

What Orange Book or FDA pathway linkage is implied?

Many brand-versus-generic patent suits tie to ANDA litigation and Orange Book-listed patents. To state which Orange Book patents were implicated, the asserted patent numbers must be matched to Orange Book listings by NDA/ANDA product.

Without the asserted patent list and the product, Orange Book mapping cannot be performed.

How strong is the Medicines Company patent estate in this matter?

A defensible estate strength assessment requires:

• the number of asserted patents and families,
• their remaining term at the time of filing and at present,
• whether patents were deemed valid,
• whether the court adopted plaintiff-preferred constructions,
• whether patents were later invalidated in other forums.

None of those determinants can be computed from the docket number alone.

Company-by-company positioning: Medicines Company vs APP Pharmaceuticals

Plaintiff (The Medicines Company):

• typically positions with a claim set tied to core commercial product protection and potential exclusivity leverage.

Defendant (APP Pharmaceuticals LLC):

• typically contests noninfringement and/or invalidity and uses claim construction to narrow claim scope.

A litigation-grade comparison must specify which defenses were raised and which were accepted by the court. That requires docket filings.

Key takeaways

• Medicines Company v. APP Pharmaceuticals LLC (1:10-cv-00476, D. Del.) is a patent infringement dispute whose business impact hinges on the docket’s final disposition and any settlement terms.
• The case number and parties alone do not contain the asserted patent identities, procedural milestones, or the dispositive ruling required for an accurate litigation summary.
• For decision-making on entry risk and IP strategy, the controlling artifacts are the complaint’s asserted patents, claim construction orders, dispositive rulings, and any settlement dismissal language.

FAQs

1. What patents were asserted in Medicines Company v. APP Pharmaceuticals LLC 1:10-cv-00476?
2. Did the court issue a Markman order in 1:10-cv-00476, and what claim terms were construed?
3. Was 1:10-cv-00476 resolved by summary judgment, dismissal, or settlement?
4. Do the case filings map to any ANDA or Orange Book listed patents?
5. What design-around or noninfringement findings affected later competitor launches tied to this estate?

References (APA)

1. U.S. District Court for the District of Delaware. Medicines Company v. APP Pharmaceuticals LLC, No. 1:10-cv-00476.